Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06787586 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
A Phase 1 study of Atopic Dermatitis (AD) and Normal Volunteers, sponsored by Attovia Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 17
- Study locations
NCT06787586: Active Phase 1 study of Atopic Dermatitis (AD) and Normal Volunteers, sponsored by Attovia Therapeutics.
NCT06787586 is a Phase 1 study of Atopic Dermatitis (AD) and Normal Volunteers that is active but no longer recruiting, run by Attovia Therapeutics. The registered enrollment target is 108 participants, above the 95-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (14% higher). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06787586, a Phase 1 study of Atopic Dermatitis (AD) and Normal Volunteers, is active but no longer recruiting, sponsored by Attovia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 17
- Study locations
Study Summary
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Primary Outcome
The primary analysis will describe the incidence of AEs and laboratory abnormalities. AEs will be coded according to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA, version 26.1 or the current version). Their severity will be graded using the NCI CTCAE v5.0 or the current version.
Conditions Studied
Interventions
- DRUG ATTO-1310
- DRUG ATTO-1310 Placebo
Study Locations (17)
California
- Attovia Clinical Site 103 - Encinitas
- Attovia Clinical Site 116 - Rocklin
- Attovia Clinical Site 107 - Sacramento
Ontario
- Attovia Clinical Site 111 - Newmarket
- Attovia Clinical Site 112 - Peterborough
- Attovia Clinical Site 113 - Toronto
Florida
- Attovia Clinical Site 109 - Coral Gables
- Attovia Clinical Site 118 - Margate
New York
- Attovia Clinical Site 114 - New York
- Attovia Clinical Site 119 - New York
Quebec
- Attovia Clinical Site 105 - Montreal
- Altasciences - Montreal
Indiana
- Attovia Clinical Site 102 - Plainfield
Missouri
- Attovia Clinical Site 104 - Saint Joseph
Nevada
- Attovia Clinical Site 106 - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What the registry record for NCT06787586 still lists
NCT06787586 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, above the 95-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (14% higher).
The record links to 4 conditions, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 2 interventions - of which ATTO-1310 is the first listed.
NCT06787586 lists 17 locations in 10 states (California, Ontario, Florida).
Frequently Asked Questions
What is clinical trial NCT06787586 about?
NCT06787586 is a clinical study titled "Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus". The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310...
What is the current status of trial NCT06787586?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2025-01-14. Estimated completion is 2026-05.
What conditions does trial NCT06787586 study?
This clinical trial studies the following conditions: Atopic Dermatitis (AD), Normal Volunteers, Atopic Eczema, Chronic Pruritus.
What interventions are being tested in trial NCT06787586?
The interventions under investigation include: ATTO-1310 (DRUG), ATTO-1310 Placebo (DRUG).
Who is sponsoring clinical trial NCT06787586?
This trial is sponsored by Attovia Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06787586 being conducted?
This trial has 17 study locations across California, Florida, Indiana, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
RECRUITING · Phase 1
-
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
RECRUITING · Phase 1
-
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
RECRUITING · Phase 1
-
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 1
-
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI